European Commission approves Biocon's Pebrilzo as first biosimilar under new tailored clinical approach

Biocon has secured European Commission marketing authorisation for Pebrilzo, its pertuzumab biosimilar, marking what the company describes as the first biosimilar approval under the EMA's tailored clinical approach.
Biocon announced on 18 November 2026 that the European Commission had authorised Pebrilzo, a biosimilar to Perjeta (pertuzumab), for specified HER2-positive breast cancer treatment settings following a positive CHMP opinion in September.
The European decision is a separate regulatory milestone from Pebrilzo's US FDA approval announced on 16 November and highlights the EMA's evolving evidence requirements for biosimilar development; the authorisation does not establish clinical superiority over Perjeta or confirm immediate commercial availability in every European market.
Field | Content |
Company | Biocon |
Medicine | Pebrilzo (pertuzumab biosimilar) |
Reference Medicine | Perjeta |
Regulatory Authority | European Commission |
Approval Announcement | 18 November 2026 |
Approval Type | EU biosimilar marketing authorisation |
Therapeutic Area | Oncology |
Indication | Specified HER2-positive breast cancer treatment settings |
Molecular Target | HER2 |
Product Classification | Monoclonal antibody biosimilar |
Regulatory Pathway | EMA tailored clinical approach |
Regulatory Distinction | Described by Biocon as the first biosimilar approved under the new tailored clinical approach |
Earlier EU Milestone | Positive CHMP opinion in September 2026 |
Separate US Milestone | FDA approval announced 16 November 2026 |
Clinical Interpretation | Biosimilar approval does not establish superiority over the reference medicine |
Commercial Implications | EU marketing authorisation enables potential market entry subject to applicable access and commercial arrangements |
Primary Source | https://www.biocon.com/biocons-pertuzumab-gets-marketing-authorization-in-eu-first-biosimilar-approved-under-new-tailored-clinical-approach/ |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


댓글